Riociguat is NOT indicated for heart failure
Riociguat is contraindicated for use in patients with heart failure and should not be prescribed for this indication. The drug is FDA-approved exclusively for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH), not for heart failure treatment 1.
Why Riociguat Should Not Be Used in Heart Failure
Absence from Guideline-Directed Medical Therapy
The most recent and authoritative ESC Heart Failure Guidelines (2016) provide comprehensive treatment algorithms for heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF), and heart failure with mid-range ejection fraction (HFmrEF) 2. Riociguat is completely absent from all treatment recommendations across all heart failure phenotypes.
The established pharmacological treatments for symptomatic HFrEF include:
- ACE inhibitors (Class I, Level A)
- Beta-blockers (Class I, Level A)
- Mineralocorticoid receptor antagonists (Class I, Level A)
- Sacubitril/valsartan (Class I, Level B)
- Diuretics for congestion (Class I, Level B)
None of these guidelines mention riociguat as a therapeutic option 2.
FDA Drug Label Contraindication
The FDA drug label explicitly warns against using riociguat with certain medications commonly prescribed in heart failure. Riociguat is contraindicated with nitrates (such as isosorbide dinitrate) due to severe hypotension risk 3. Since nitrates are frequently used in heart failure patients with concomitant angina, this creates a significant safety concern 3.
Failed Clinical Trial Evidence
While riociguat showed some hemodynamic improvements in research settings, these did not translate to clinically meaningful outcomes:
Phase IIb trial in HF with systolic dysfunction (2013): Although riociguat improved cardiac index and reduced vascular resistance, the primary endpoint of reducing mean pulmonary artery pressure was not met 4. This represents a failed primary outcome.
DYNAMIC trial in HFpEF (2022): While riociguat improved cardiac output at rest, it did not change clinical symptoms and led to more treatment discontinuations compared to placebo 5. The drug showed hemodynamic effects without symptomatic benefit—a disconnect that argues against clinical use.
DILATE-1 study (2014): In patients with PH and HFpEF, riociguat had no significant effect on mean pulmonary artery pressure, the primary endpoint 6.
The Approved Indication: Pulmonary Hypertension
Riociguat's evidence base and regulatory approval are specifically for PAH and CTEPH, not heart failure 1. The CHEST guidelines (2014) recommend riociguat for:
- Treatment-naive PAH patients with WHO FC II symptoms (Grade 2B)
- Improving 6-minute walk distance, WHO functional class, and delaying clinical worsening
This is fundamentally different from heart failure treatment, where the goals are reducing mortality, preventing hospitalizations, and improving quality of life through neurohormonal blockade.
Critical Safety Concerns
Hypotension Risk
Riociguat causes vasodilation and can precipitate severe hypotension, particularly problematic in heart failure patients who may already be volume depleted or hypotensive 3. The 2025 ESC consensus on HFrEF with low blood pressure emphasizes careful management of hypotension-inducing medications 7, and adding riociguat would only compound this risk.
Drug Interactions
Riociguat cannot be combined with PDE5 inhibitors (sildenafil, tadalafil) due to severe hypotension risk 1, 3. This limits therapeutic options and creates dangerous interaction potential.
Lack of Mortality Benefit
Unlike proven HF therapies (ACE inhibitors, beta-blockers, MRAs, SGLT2 inhibitors), riociguat has never demonstrated mortality reduction in heart failure populations. The 2022 AHA/ACC/HFSA guidelines emphasize treatments with proven mortality and morbidity benefits 8—riociguat does not meet this standard.
Clinical Bottom Line
Do not prescribe riociguat for heart failure. The drug:
- Has no guideline support for HF treatment
- Failed to meet primary endpoints in HF clinical trials
- Carries significant hypotension and drug interaction risks
- Lacks evidence for mortality or hospitalization reduction
- Is contraindicated with commonly used HF medications (nitrates)
If a heart failure patient has concomitant PAH or CTEPH documented by right heart catheterization, riociguat may be considered for the pulmonary hypertension indication specifically, but this requires careful evaluation by a pulmonary hypertension specialist, not as heart failure therapy 1.
For heart failure treatment, adhere to guideline-directed medical therapy: ACE inhibitors/ARNIs, beta-blockers, MRAs, and SGLT2 inhibitors for HFrEF 2, 8; SGLT2 inhibitors for HFpEF 8.